The role of natriuretic peptides for the diagnosis of left ventricular dysfunction by Palazzuoli, Alberto et al.
Hindawi Publishing Corporation
The Scientific World Journal
Volume 2013, Article ID 784670, 10 pages
http://dx.doi.org/10.1155/2013/784670
Review Article
The Role of Natriuretic Peptides for the Diagnosis of Left
Ventricular Dysfunction
Alberto Palazzuoli, Matteo Beltrami, Gaetano Ruocco, Marco Pellegrini, and Ranuccio Nuti
Department of Internal Medicine and Metabolic Diseases, Cardiology Section, Le Scotte Hospital, 53100 Siena, Italy
Correspondence should be addressed to Alberto Palazzuoli; palazzuoli2@unisi.it
Received 17 June 2013; Accepted 20 August 2013
Academic Editors: X. Ai, Y. Wang, and Y. Yang
Copyright © 2013 Alberto Palazzuoli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Natriuretic peptides (NPs) are entered in current guidelines for heart failure (HF) diagnosis andmanagement because of their high
specificity and sensibility in screening patients with acute dyspnea. Due to their availability and relatively low cost, they became the
first step examinations in HF patients evaluation at hospital admission together with clinical and chest radiography examination.
NPs are released following any cardiac haemodynamic stress due to volume or pressure overload and should be considered as a
mirror of cardiac condition helping in recognizing patients with poor outcome. Moreover, the exact role of NPs in early HF stages,
in isolated diastolic dysfunction, and in general population is questioned. Several promising reports described their potential role;
however, the wide cut-off definition, inclusion criteria, and intrinsic measurement biases do not actually consent to their clinical
application in these settings. A multimodality strategy including both NPs and imaging studies appears to be the best strategy to
define the cardiac dysfunction etiology and its severity as well as to identify patients with higher risk. In this review, we describe
the current and potential role of NPs in patients with asymptomatic cardiac insufficiency, evaluating the requirement to obtain a
better standardization for imaging as for laboratory criteria.
1. Introduction
Research regarding the role of serum biomarkers in patients
with cardiovascular diseases has grown exponentially over
the last ten years. In particular, multiple novel biomarkers
have been developed for heart failure (HF), due in part to a
well-established pathophysiology, including cardiac dysfunc-
tion, neurohormonal activation, and hydrosaline retention
[1–3]. At the same time, the diversity of HF biomarker
development reflects the heterogeneity of patients, with mul-
tiple etiologies, phenotypes, and comorbidities. In general,
four categories of HF biomarkers have been developed, and
these biomarkers should reflect the pathophysiology and
heterogeneity of HF. The 4 categories are biomarkers (1) of
cardiac injury, (2) adrenergic overdrive, (3) inflammation, (4)
oxidative stress, and (5) systemic organ damage [4].
Although the classification of biomarkers helps differenti-
ate each type, this also highlights a potential shortcoming of
biomarker development: the fact that they are often studied
in isolation, though this trend is recently changing. The
ideal laboratory tool fulfills the three criteria outlined by
Morrow and de Lemos. Traditionally, three different groups
of biomarkers have been identified: (1) laboratory tests, such
as natriuretic peptides (NPs) and troponins are defined as
“laboratory ormolecular biomarkers,” (2) those related to sig-
nal, imaging, and functional tests are defined as “functional
biomarkers,” and (3) those related to genetic polymorphisms
and other genomic tests are defined as “genetic biomarkers.”
In this sense, an integrate approach appears mandatory to
establish early diagnosis and to optimize the outcome. More-
over, a cardiovascular biomarker can be classified in multiple
categories according to its pathophysiological characteristics
and/or clinical use. Although this classification is arbitrary,
since each index can contain several of these characteristics,
it is useful for interpreting the value of an individual clinical
biomarker.
Regarding laboratory biomarkers, Morrow and de Lemos
outlined the three major criteria of a clinically useful
biomarker: (1) accurate, reproducible measurements must be
rapidly available to the clinician at a reasonable cost; (2)
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the biomarker must provide additional information beyond
careful clinical assessment; (3) knowledge of the measured
level should aid in medical decision making [5]. In clinical
practice, it is hard to find a specific biomarker that contains
all these characteristics. For example, significant troponin
increase in patients with chest pain and any specific ST wave
alterations address physician towards an ischemic etiology;
similar model should be applied in patients with dyspnea
in the absence of specific chest radiography or ECG signs
whereby an increase inNPs levels leads toHF diagnosis [4, 6].
In the last decade, an “explosion” of data regarding the
use of biomarkers in cardiovascular diseases is evident in
the literature. This has happened for several reasons: to
facilitate diagnosis, improve prognosis both early and late in
the course of the disease, and guide management. However,
each biomarker has various strengths and weaknesses: some
requirements are linked to chemical detection (reproducibil-
ity and accuracy, in vivo and in vitro stability, low cost,
sensitivity and availability, and international standardization
reference tested for gender and age), while others need to
respond to clinical requirements (good diagnostic and prog-
nostic accuracy, useful in therapymonitoring, and reasonable
cost-effectiveness ratio) [5, 7].
Laboratory tests are able to identify serial mechanisms
potentially involved in the genesis of HF; however, it appears
hard to find a single specific biomarker including diagnostic,
prognostic, and clinical information all together at the same
time. In this context, it appears difficult to identify through
laboratory tests the early mechanisms that cause myocardial
damage, in order to recognize those subjects at risk to
develop the HF syndrome. Frequently, a single biomarker
demonstrates exciting results in preliminary studies that
cannot be confirmed later in prospective multicenter studies
[6].
Early diagnosis of HF depends on the availability of
specific, accurate, and effective markers of the disease. For
this reason, a multimarker strategy including new and old
biomarkers together with traditional diagnostic tools has
been recently proposed.
Recently, Braunwald classified biomarkers on the basis
of each pathophysiologic process that is involved in HF [7].
This classification is now universally accepted: inflammation,
neurohormones, myocyte Injury, Oxidative Stress, and extra-
cellular matrix remodelling biomarkers (Table 1).
In the HF setting, patients present with various clinical
presentations and in distinct stages of progression; therefore,
an ideal biomarker should be able to recognize not only dis-
ease severity but also the underlying causal mechanisms and
the risk profile [8]. Moreover, application in clinical practice
requires validation of each biomarker inmultiple studies with
a unique cutoff, given the categorical nature of the physician
decision making. Ideally, this would include studies yielding
diagnostic, prognostic, and therapeutic values further vali-
dated in the “real-world” setting for example, the evidence
that triage guided by biomarkers improves the quality of
treatment and shortens the diagnostic process. Probably an
ideal biomarker that is able to include all this information
is far from being conceived. Perhaps a multimarker strategy
as applied in the acute coronary syndrome could be useful
to better understand the etiology of HF and its severity and
to assess early as well as long term risks. In this context,
significant troponin increase associated with a high level of
NPs is able to identify patients withmyocardial infarction and
the poor outcome for HF development [9, 10].
2. Haemodynamic and Nonhaemodynamic
Determinants in Acute Heart Failure
Multiple pathophysiologic factors contribute to the develop-
ment of HF and cardiac impairment. For simplicity, three
principal disorders predominate: pump dysfunction, neu-
rohormonal activation, and salt-water retention. However,
the clinical presentation resulting from these underlying
disorders varies greatly, in part determined by hemodynamic
status, primary cardiac disorder, systemic pressure, and organ
perfusion/damage [11, 12]. A recent report has divided the
acute decompensated HF syndromes on the basis of primary
cardiac dysfunction, coronary artery disease presence, and
clinical presentation [1, 10]. Further subclassification by type
of cardiac dysfunction has been proposed: most patients
with HF have both systolic and diastolic left ventricular (LV)
dysfunction, but in some cases the syndrome can occur with
isolated systolic or diastolic dysfunction. HF with preserved
left ventricular ejection fraction (HFpEF) is characterized
by a nondilated, usually hypertrophied, left ventricle in
which left ventricular ejection fraction (LVEF) is preserved
at rest, and the parameters of LV relaxation and filling are
markedly deranged. PatientswithHFpEF are a heterogeneous
and understudied group that includes subjects with both
hypertensive heart disease and hypertrophic cardiomyopathy
[11].
However, systolic HF is itself a heterogeneous condition
with several mechanisms acting as potential contributors:
preload, afterload, cardiac contractility and filling, peripheral
vascular resistance, and heart rate variability are all important
determinants of cardiac performance. The presence of viable
myocardium, extension of necrosis, and severity of coronary
disease are further determinants of LV function. One of
the determinants is the diastolic function that is intimately
related to cardiac afterload, and this load dependence is
amplified in HF [12]. Acute increases in afterload lead to
prolongation of isovolumic relaxation. Loading increases in
systolic pressure have further impairing effects on the dias-
tole. This increased passive stiffness, together with abnormal
relaxation, will shift the diastolic pressure-volume relation
curve upward and to the left, with retrograde elevation
of LV end-diastolic, left atrial, and pulmonary pressures.
Reduced myocardial release, augmented myocardial mass
and stiffness, and delayed inactivation are all elements that
contribute significantly to an increase in LV filling pressure
andwall tension [13]. Beyond the hemodynamic factors, there
are at least two principal actors playing an equally influential
role in HF establishment and maintenance: neurohormonal
activation and hydrosaline retention. Bothmechanisms cause
peripheral vasoconstriction that results in an increased
LV afterload, the activation of inflammatory pathways, the
increase of growth factors and endothelial dysfunction, and
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Table 1: Classification of biomarkers for early cardiac damage identification.
Markers of neurohormonal activation
(i) Natriuretic peptides (ANP, BNP, CNP, and related peptides)
(ii) Markers of renin angiotensin aldosterone system activity
(iii) Arginine vasopressin
Markers of cardiac injury
(i) Cardiac troponins (cTnI, cTnT)
(ii) Heart-type fatty-acid protein
(iii) Myosin light-chain kinase I
Markers of inflammation and matrix remodelling
(i) Matrix metalloproteinases (MMPs) and MMPs tissue inhibitors
(ii) C-reactive protein
(iii) Cytokines and related receptors (interleukins IL-1, IL-2, IL-6, IL-8, and IL-18,
TNF-𝛼, osteoprotegerin, and Fas ligand)
Markers of systemic organ damage (i) Renal injury: creatinine, BUN, NGAL, and cystatin C(ii) Hepatic injury: transaminases and gamma-glutamyl transferase
Aspecific laboratories indexes
(i) Anemic status and erythropoietin endogenous levels
(ii) Low albumin levels
(iii) Hyponatremia
(iv) Carbohydrate antigen 125
B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP), C-type natriuretic peptide, tumor necrosis factor-𝛼 (TNF-𝛼), blood urea nitrogen,
neutrophil gelatinase-associated lipocalin (NGAL).
Cardiac
performance
Cardiac output
Heart rate
Contractility
Preload Afterload
∙ Synergistic LV contraction
∙ Wall integrity
∙ Valvular competence
Figure 1: Haemodynamic and intrinsic cardiac factors influencing
filling pressure and cardiac performance.
the induction of oxidative stress.The increased fluid overload
results in elevated intracardiac pressure as well as pulmonary
congestion [14]. It would be difficult to obtain all this
information by a single biomarker; therefore, a multimarker
strategy including clinical laboratory and imaging parameters
is currently the most appropriate strategy. Among all the
potential biomarkers, the ones that probably contain the
most clinical hemodynamic and systemic information are
NPs. Such dowries are due to its secretion mechanism:
NPs are increased as a consequence of augmented cardiac
pressure, volume overload and wall tension. NPs levels are
also mediated by means of the renin-angiotensin system and
neuroendocrine overdrive; therefore, for specific counter reg-
ulatory mechanisms, levels are augmented during idrosaline
status retention. For all these reasons, NPs are able to provide
some additive and complementary information with respect
to the traditional tools in the HF setting [15] (Figure 1).
3. The Current and Potential Role of NP in
Heart Failure
The discovery of NPs as diagnostic biomarkers has been one
of the most important advances in the diagnosis of heart
failure. Prior to NPs, several studies suggested the need to
improve diagnosis, especially with the increasing prevalence
of heart failure in the United States [26]. However, diagnosis
may be delayed, due to the aspecificity of symptoms and
the previous lack of a rapid, easily accessible, bedside gold
standard protocol to facilitate diagnosis.
3.1. NP in Emergency Setting. The utility of NPs was ini-
tially demonstrated in emergency department (ED) patients
presenting with acute dyspnea. B-type natriuretic peptide
(BNP) levels were a more accurate predictor of HF diag-
nosis than history, physical exam and routine laboratory
tests [16]. The Breathing Not Properly trial showed that a
BNP level ≤ 100 pg/mL yielded 90% sensitivity and 76%
specificity in separating cardiac from noncardiac etiologies
of dyspnea [17]. N-terminal pro-B-type natriuretic peptide
(NT-proBNP) has also been studied in the ED, during
hospitalization and even in the outpatient setting, to facilitate
diagnosis, ascertain severity of disease, confirming its utility
as an excellent biomarker for risk stratification as well as
subsequent resource utilization [27].TheNP literature is now
extensive and confirms results from previous meta-analysis
demonstrating NP’s role in diagnosing cardiogenic dyspnea
and reducing admission rates [28]. Elevated NPs levels
also directly correlate to the respective functional NYHA
class, intraventricular pressure, and pulmonary pressure and
inversely to cardiac output [18].
3.2. NP in Risk Stratification. NPs measurements appear to
be a useful tool for risk stratification; in fact, high levels
are associated with recurrent hospitalization and risk of
sudden death. Several studies that used natriuretic peptides
in predischarge indicate that BNP levels appear to be the
strongest predictor for identifying subsequent death or hos-
pital admission within 6 months [25, 29]. In the Australia-
New Zealand Heart Failure Group Trial in patients with
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chronic HF and reduced systolic function, levels of NT-
proBNP above the median were associated with an increased
risk for new decompensate HF events and all-cause mortality
during the 18-month followup [19]. The largest study is the
Valsartan Heart Failure (Val-HeFT) trial in patients with
chronicHFwho received the recommendedmedical therapy:
an increment of 500 ng/L above the baseline concentration
of NT-proBNP carried an increased adjusted risk of 3.8%
for mortality and 3.0% for hospitalization for HF. On a
multivariate analysis, once again NT-proBNP was ranked
as the first prognostic factor in these patients, proving to
be independent of and more powerful than traditional risk
factors, such as NYHA class, age, left ventricular dilation, or
renal dysfunction [30].
3.3. NP and Cardiac Performance. NPmeasurements are also
related to several indexes of systolic and diastolic functions.
Traditionally, its samples are linearly increased in relation to
the degree of systolic dysfunction and cardiac enlargement
[20, 31]. Invasive measurements are the reference standard
for establishing pulmonary pressure and filling pressure
elevation in all subjects with dyspnea, but noninvasive
methods of estimating LV filling pressure and pulmonary
pressure are entering the current practice. Recently, it has
been demonstrated that BNP in systolic HF is progressively
increased in relation to the degree of diastolic dysfunction,
the severity of mitral valve regurgitation, and right ventric-
ular dysfunction [32]. NPs also reflect elevated LV filling
pressure and pulmonary capillary wedge pressure measured
invasively with good accuracy and specificity. On the con-
trary, sensitivity is often modest particularly in patients with
preserved systolic function and normal LV volumes [21, 33].
The best correlation between BNP and invasivemeasurement
has been demonstrated with end diastolic wall stress and
end diastolic pressure. This suggests that diastolic stretch
is one of the major determinants of NP induction [34].
Finally, in a more recent study that compared BNP levels
with venous pressure, capillary wedge pressure, and diastolic
filling pattern, evaluated by echo, authors showed that as BNP
cutoff >400 pg/mL is able to identify patients with higher
wedge pressure, it correlates well with all hemodynamic
parameters [35].
Some reports have also demonstrated a positive correla-
tion between NP and several markers of LV filling measured
traditionally by transmitral Doppler andmore recently by tis-
sueDoppler aswell as E/E1 ratio.However, NPmeasurements
are not able to differentiate between systolic and diastolic
dysfunctions [22]. A combined approach with echo Doppler
parameters and BNP data seems to be able to stratify patients
with systolic dysfunction better. Therefore, tissue Doppler
analysis demonstrated that BNP in the gray zone between 8
and 15 is able to differentiate patients with increased filling
pressure providing a better stratification. The integrative
approach could also improve the diagnostic accuracy in
patients with systolic dysfunction and abashed echo diastolic
parameters [36]. NP showed a significant elevation together
with other parameters of the right ventricular function,
increasing with greater dilatation and impairment, as with
right and ventricular longitudinal dysfunction. Right ventric-
ular systolic dysfunction is an independent prognostic factor
in patientswithmoderate to severeHF, and it is strictly related
to reduced effort tolerance and exercise capacity. In patients
with right ventricular pressure overload, NP levels correlated
with mean pulmonary artery pressure, right atrial pressure,
RV end-diastolic pressure, and total pulmonary resistance
[21]. The previously cited measurements have important
prognostic power, and the combination of laboratory and
imaging data provide a more precise risk prediction for
rehospitalization and mortality in patients with HF.
3.4. NP for Therapy Monitoring. Many studies have demon-
strated that there is a reduction inNP after the administration
of loop diuretics and other drugs during the acute HF phases.
This is due to reduced filling pressure and wall stiffness
into LV as well as a decrease in idro-saline retention and
in neurohormonal overdrive. In a chronic outpatients group
STARS-BNP trial, it was clearly shown that a BNP-guided
strategy reduces the incidence of death and rehospitalization
for HF [23]. More definitive data were reported by Cohen-
Solal in acute HF: patients with BNP reduction over 30%
after therapy showed a significant reduction in mortality and
rehospitalization compared with nonresponders [24]. These
results suggest that the variations in BNP concentrations
after therapy for acute HF are independent and objective
predictors of therapy’s adequacy.
For all the previously cited reasons, NP measurement
entered in the last HF guidelines providing additive diagnos-
tic and prognostic information with respect to the previous
approach (Table 2).
Such dowries are due to its secretion mechanism: NP, are
increased as a consequence of augmented cardiac pressure,
volume overload, and wall tension. NP levels are also medi-
ated by means of the renin-angiotensin system and neuroen-
docrine overdrive; therefore, for specific counterregulatory
mechanisms, levels are augmented during idro-saline status
retention. Even if NP cannot be considered as “araba fenice,”
they should be regarded as the best candidates to provide
some additive and complementary information with respect
to the traditional tools in the HF setting.
4. Natriuretic Peptides and
Diastolic Dysfunction
HFpEF accounts for around 50% of patients with acute
decompensated HF. The diagnosis, at times, may be difficult.
Three major conditions need to be recognized: (1) signs and
symptom of heart failure, (2) preserved systolic function
(EF ≥50 %), and (3) left ventricular diastolic dysfunction
(increased myocardial stiffness, elevated filling pressures,
and abnormal diastolic relaxation) [37]. In clinical prac-
tice, differentiating HFpEF from heart failure with reduced
ejection fraction (HFrEF) is often difficult on the basis of
history, physical examination, chest X-ray, and ECG alone.
Assessment of these patients demonstrates a left and upward
shift in their end-diastolic pressure volume curve shifted
with cardiac chambers dilatation without severe increase
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Table 2: Clinical trials regarding NPs measurement for diagnosis, cardiac dysfunction, and therapy monitoring.
Author Clinical setting Patients Study design Main findings
Maisel
et al. [16]
Patients with
acute decom-
pensated heart
failure
(ADHF).
464
Entrance criteria included a BNP level
>100 pg/mL.
Admitted patients were divided into two
groups based on B-type natriuretic peptide
(BNP) levels above and below 200 pg/mL to
study differences in outcome rates.
The BNP levels can predict future outcomes and
thus may aid physicians in making triage
decisions about whether to admit or discharge
patients. Emerging clinical data will help further
refine biomarker-guided outpatient therapeutic
and monitoring strategies involving BNP.
Luchner
et al. [17]
Patients with
ADHF 1086
Primary endpoint was hospital admission;
secondary endpoints were
intermediate/intensive care unit (IMC/ICU)
admission, length of stay, rehospitalization and
death, or rehospitalization.
Knowledge of N-terminal pro-B-type natriuretic
peptides (NT-proBNP) had no significant effect
on the primary endpoint hospital admission and
the secondary endpoints. Patients with high open
NT-proBNP (>1800 pg/mL) were more likely to
be admitted to the hospital and IMC/ICU,
whereas patients with low open NT-proBNP
(<150 pg/mL) were less likely to be admitted
compared with patients with blinded NT-proBNP.
Bettencourt
et al. [18]
Patients with
ADHF 182
The goal of the study was to evaluate the value
NT-proBNP in predicting death or hospital
readmission after discharge of HF patients.
Variations in NT-proBNP levels are related to
hospital readmission and death within 6 months.
NT-proBNP levels are potentially useful in the
evaluation of treatment efficacy and might help
clinicians in planning discharge of HF patients.
Masson
et al. [19]
Patients with
chronic and
stable HFs.
3916
This work aimed to provide a direct
comparison of the prognostic value of BNP and
NT-proBNP in patients with chronic and stable
HFs.
BNP and NT-proBNP showed subtle differences
in their relation to clinical characteristics and
prognostic performance in a large population of
patients with chronic and stable HF. They were
the most powerful independent markers of
outcome in HFs.
Troughton
et al. [20, 21]
Patients with
systolic heart
failure (SHF).
106
This study was designed to characterize the
importance of echocardiographic indexes as
determinants of BNP levels in patients with
SHF.
Plasma BNP levels are significantly related to
diastolic indexes measured from tissue Doppler
imaging (TDI) and color M-Mode in SHF. BNP
levels reflect the severity of diastolic abnormality,
right ventricle (RV) dysfunction, and mitral
regurgitation. These findings may explain the
powerful relationship of BNP to symptoms and
prognosis in SHF.
Bistola
et al. [22]
Patients with
advanced
chronic HF
(CHF).
102
Patients with CHF were studied by
2-dimensional conventional and TDI
echocardiographies of the left and right
ventricles. Patients were followed for 6 months
for major cardiovascular events.
RV TDI systolic velocity, dilated cardiomyopathy,
digoxin treatment, and female gender were
associated with increased cardiovascular death.
RV TDI indexes combined with increased plasma
BNP additively predict adverse cardiac outcomes
in advanced CHF.
Jourdain
et al. [23]
New York
Heart
Association
functional
class II to III
patients with
CHF
220
Patients with CHF considered optimally
treated were randomized to medical treatment
according to either current guidelines or a goal
of decreasing BNP plasma levels <100 pg/mL.
The primary combined endpoint was
CHF-related death or hospital stay for CHF.
In optimally treated CHF patients, a BNP-guided
strategy reduced the risk of CHF-related death or
hospital stay for CHF. The result was mainly
obtained through an increase in ACEI and
beta-blocker dosages.
Cohen-Solal
et al. [24]
Patients with
ADHF 1327
The purpose of this analysis was to examine
whether decreases in BNP levels during the
first few days of hospitalization were associated
with greater survival in patients with ADHF.
Patients with lowered BNP on treatment for
ADHF had reduced mortality risks (31- and
180-day) compared to those with little or no BNP
decrease. These results suggest that early lowering
of BNP predicts both short- and long-term
mortality risks. BNP reduction may therefore
serve as a suitable prognostic marker of all cause
mortality.
Richards
et al. [25]
Patients with
ischemic LV
dysfunction
297
They sought to assess plasma concentrations of
NT-proBNP and adrenomedullin for the
prediction of adverse outcomes and responses
to treatment.
In patients with established ischemic LV
dysfunction, plasma concentrations of
NT-proBNP and adrenomedullin are independent
predictors of mortality and HF. Carvedilol
reduced mortality and HF in patients with higher
pretreatment plasma NT-proBNP and
adrenomedullin.
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of myocardial mass. Invasive measurement is the reference
standard for establishing LV end diastolic pressure; however,
this is not currently feasible in all subjects with preserved
systolic function; therefore, echo-Doppler measuring is the
most reliable method of estimating LV pressures [38]. NPs
levels are known to be elevated in patients with increased
ventricular filling pressures. Pressure overload and ventric-
ular volume expansion are the causes of high levels of this
cardiac neurohormone. Hence, NPs can predict diastolic dys-
function increasingly in patients with either symptomatic or
asymptomatic diastolic abnormalities. Lubien et al. detected
how this peptide can confirm the diagnosis of diastolic heart
failure using two-dimensional Doppler echocardiography
[39].Themitral inflow velocitywas recorded inmost patients;
when filling pressures are elevated, E velocity increases, and
A velocity decreases producing a restrictive pattern. Tissue
Dopplermeasurements ofmitral annular side show a reduced
early diastolic velocity (Ea); by this method, the E/Ea ratio
can reliably estimate the ventricular filling pressures with
reasonable accuracy. If the E/Ea ratio is <8, filling pressure is
normal with normal myocardial relaxation, if it is >15 filling
pressure is elevated, but if this ratio is between 8 and 15, the
assessment of diastolic dysfunction is not clear. In this case, a
rapid assay of BNP can detect diastolic dysfunction. Maeder
proposed a BNP level > 200 pg/mL to confirm the diagnosis
of heart failure with normal ejection fraction in patients with
E/Ea in the gray zone [40].
In patients with HFpEF, BNP increases according to the
degree of diastolic dysfunction: the noninvasive analysis of
HF with preserved systolic function is often difficult to estab-
lish, LV filling estimation appears particularly complicated
in those patients with pseudonormal pattern and E/Ea ratio
between 8 and 15. In these patients, BNP can detect diastolic
filling pressure helping in the screening and grading its sever-
ity [41]. These findings have been validated by a comparison
between Doppler and invasive hemodynamic measurements,
confirming the great reliability of NT-proBNP in diagnosing
isolated diastolic dysfunction [42, 43]. In the same setting,
NPs are as well related to atrial volume enlargement which is
considered an indirect marker of filling pressure even in the
absence of primitive mitral valve disease, Figure 2.
5. Natriuretic Peptides as a Screening Tool in
the General Population
Although NPs have been emerged as a useful tool in the
diagnosis of acute HF and are entered also in the American
Guideline algorithms, their significance as a screening device
for the general population, namely, to detect asymptomatic
patients with LV dysfunction, is currently debated [44]. In
the general population, NPs measurements are affected by
several cardiac and noncardiac variables (see the following
paragraph) that need to be taken into account during the
patient’s evaluation. Before the clinical syndromes of HF are
displayed, several haemodynamic and LV pressure-volume
modifications occur: the first step is an abnormal systolic
or diastolic function that is succeeded by increased end
diastolic pressure and wall tension. After this stage, the LV
pressure-volume curve shifts downward to the right; in the
remodelled heart, there is a further increase in LV filling,
impaired relaxation with stiffness, and increased left atrial
pressure. Clinical syndromes ofHFwith symptoms of fatigue,
dyspnea, dizziness and so forth, begin to be evident at this
stage, and it will be clearly evident when increased left
chamber pressure reflects a raise in pulmonary pressures
[45]. Importantly, these clinical syndromes represent the tip
of the iceberg, as it would be ideal to recognize cardiac
remodelling before the clinical syndrome is apparent during
early stages (stages A and B) of the last HF classification.
The importance to intercept patients during these stages
is confirmed by epidemiological data showing that asymp-
tomatic patients with mild to moderate LV dysfunction have
worse outcomes. Whether NPs screening would recognize
this process before clinical manifestations become evident is
debated. Some reports seem to confirm a role in this context;
in Olmstead county a study on 2042 subjects NTpro-BNP
and BNP demonstrated high sensitivity and specificity in
detecting moderate systolic and diastolic dysfunctions (86
and 81%, resp.) particularly in older patients [46]. In another
report with a 3-year median followup, NT-proBNP was the
strongest predictor of mortality and hospital admission in
asymptomatic patients with evident cardiac dysfunction. Its
values increased with the severity of cardiac dysfunction
[47]. Opposite data were reported from Framingham in
detecting elevated LV mass and systolic dysfunction. How-
ever, this study included both patients at a high risk and
after myocardial infarction, including a wide range of values
[48]. More recently, Costello-Boerrigter et al. found that NT-
proBNP is an effective tool to make out patients with systolic
dysfunction, while the identification of diastolic dysfunction
was less effective [49].However, the combination of BNPwith
Tissue Doppler seems to be able to recognize community
patients with an increased risk and diastolic impairment
[50]. The latter data supports the double echo and laboratory
approaches in the detection of both systolic and diastolic
dysfunctions, confirming NP’s role as potential predictive
marker of adverse outcome even in asymptomatic patients.
Nevertheless, at this moment, a common cutoff does not
exist, neither for BNP nor for NT pro-BNP that is universally
accepted and clinically applicable as a screening tool in
general population.
6. Limitations of Natriuretic Peptides
Looking all together at the previously cited data, NPs mea-
surement could appear to be the best solution for few diag-
nostic and prognostic troubles in clinical practice: measuring
NPs, we are able in theory to obtain a variety of information
on HF diagnosis, severity, and identification of patients
with poor outcome. Unfortunately, several conditions can
potentially influence NPs measurements, as demonstrated by
Framingham and the Dallas Heart Study data in which a
BNP cutoff >80 was able to identify only subjects with severe
systolic dysfunction in the general population [48, 51].
Physiologic status race, sex, age, and body mass index are
all conditions that could alter NP’s synthesis and clearance
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Symptoms/signs of HF
Echo TDI
HFNEF
LVEF >50% LVEDI <97mL/m2
Evidence of abnormal LV relaxation, filling, diastolic distensibility, and diastolic stifness
Invasive measurements:
∙ PCWP >12mmHg
∙ LVEDP >16mmHg E/E󳰀 > 15 8 > E/E󳰀 < 15
Natiuretic peptides
∙ NT-proBNP >400pg/mL
∙ BNP >200pg/mL
Natiuretic peptides
∙ NT-proBNP >400pg/mL
∙ BNP >200pg/mL
∙ E/A ↓, DTe ↑
∙ Abnormal pulmonary
venous ﬂow
∙ Left atrial dilatation
∙ LVH
∙ Atrial fibrillation
TDI
E/E󳰀 > 8
∙ r > 48ms
∙ b > 0.27
Figure 2: Algorithm including both echo and NP measurements to identify patients with HF and preserved systolic function (modified by
Maeder and Kaye [40]).
[52]. Redfield et al. confirmed the impact of age and sex
on BNP observed in subjects without cardiovascular disease;
NPs measurements would be used taking into account
discriminatory values adjusted for sex and age [53]. It has
been demonstrated that age increases the levels of circulating
BNP; this is related to a decline in myocardial function and
myocardial fibrosis cardiovascular stiffness and the reduction
in clearance of natriuretic peptides typical for senescence.
However, an exact cut-off value for the difference among sam-
ple methods as for a wide variability is not well established
in the literature. NPs are also inversely related to body mass,
and patients with higher body mass index revealed lower
circulating BNP concentrations [54]. This inverse relation
may be due to increased expression of NP clearance receptors
by adipose tissue, resulting in an increased clearance of
NP in obese subjects. Race is another factor that could
influence plasma NP levels: Hispanic and Black races have
higher levels with respect to the Caucasian population for
each corresponding NYHA class [55]. Besides physiologic
conditions, several inflammatory and systemic diseases can
affect NP values [56].
6.1. Comorbidities. The most important conditions are
comorbidities like renal insufficiency (RI), diabetes, and ane-
mia that are often associated with chronic HF particularly in
older patients with more advanced stages [57]. Many studies
demonstrated that the impact of RI on NPs is independent
from the cardiac function. It depends not only on the RI
severity but also on the duration of disease [58].
Influential authors calculated that, in the presence of
these associated conditions, NPs values are at least 1/3 higher
than those in patients with normal renal function [59].
Anemia is another condition frequently associated withmore
advanced HF stages, and its correction could reduce NPs
levels [60, 61].
Cut-off limits of NPs have a grey zone in which it is
not possible to ascertain their exact diagnostic role, their
accuracy, and their predictive values [62]. This range is
between 100 and 400 for BNP and 400 and 1400 for NT-pro-
BNP; when values fall into these intermediate concentrations,
it is not possible to have enough accuracy, and further clinical
and investigational analyses need to be performed to make a
diagnosis in patients with acute dyspnea. Furthermore, the
outcome of patients who fall into this intermediate range
is not clear [63, 64]. Another limitation in clinical practice
is the moment of the measurement: NPs are released by
increased volume load and wall stretch, which are influenced
by systemic hydrosaline retention (wet versus dry). After
treatment with drugs of proven efficacy, we observed a
progressive reduction that is considered as a “measure” of
congestion. Their prognostic role also depends on the time
of measurement that reflects the volume status.
Finally, several cardiac factors can cause NPs alterations
even in the absence of increased filling pressure and frank
HF: increased LV mass, reduced right ventricular function,
mitral valve disease, high pulmonary pressure for primitive
or secondary respiratory disease, pulmonary embolism, and
atrial fibrillation are all causes of potential NP increase. Over-
all, these reasons forNPmeasurement have high sensivity but
low specificity, and laboratory test needs to be confirmed by
clinical and traditional diagnostic screening processes.
7. Conclusions
NPs are important biomarkers able to assess diagnosis and
severity of heart failure as well as predict outcome and poten-
tially guide therapy. Although echocardiography remains the
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standard regarding detailed information on cardiac perfor-
mance and structure, imaging data alone is not sufficient to
better identify patients with adverse outcome. An integrated
approach combining laboratory assays with imaging could
lead to a better identification of patients at high risk. This
behaviour seems particularly useful in some settings like
in patients with isolated diastolic dysfunction as in asymp-
tomatic patients. In patients with diastolic dysfunction, it is
sometimes difficult to confirm diagnosis, andNP should help
to identify and graduate diastolic dysfunction. In community
patients, NPs diagnostic, and prognostic values need to
be validated although it is an effective tool to recognize
patients with moderate to severe systolic dysfunction. The
major limitation consists in the lack of a universally accepted
cutoff that could permit the application of NP assays to
clinical practice in this setting. The hope is that in the future
multimarker strategies together with specificity and cut-off
improvements could accurately and early identify patients
“under the iceberg” that will develop HF syndrome. In this
ideal world biomarkers on one hand and imaging on the other
hand could converge to identify patients with higher risk.
To obtain this, we need to better standardize echo as well as
laboratory parameters.
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